This section includes information and resources about Stroke Prevention in Atrial Fibrillation (AF) for journalists: Boehringer Ingelheim press releases, background information, related press kits and a collection of images and videos. For additional information please visit NEWSCENTRE.
First patient enrolled in dabigatran study comparing anticoagulation strategies during AF ablation
Many Atrial Fibrillation patients at high risk of stroke fail to receive guideline-recommended oral anticoagulant treatment- For Non-US/Non-UK/Non-Canadian Media
Boehringer Ingelheim submits applications for approval of idarucizumab*, specific reversal agent to dabigatran etexilate (Pradaxa®), to EMA, FDA and Health Canada- For Non-US/Non-UK Media
First trial of a novel oral anticoagulant starts in prevention of recurrent stroke due to a blood clot of undetermined source- For Non-US/Non-UK/Non-Canadian Media
New data show specific antidote idarucizumab* reverses dabigatran-induced anticoagulation also in elderly and renally impaired volunteers- For Non-US/Non-UK/Non-Canadian Media